Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies

Celltrion announces positive results for its cocktail Covid-19 therapy candidates

Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings

G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research

G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc

Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron

Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Piramal Pharma takes a minority stake in Yapan Bio

The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space

Six benefits of Cloud Computing in the pharma industry

Pfizer’s Covid-19 drug 90 % effective

The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation

Asia Pacific Stroke Congress from December 9-11th

Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas

Anaemia due to iron deficiency is a cause for concern in India

According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years